An interventional study of Exercise Training in Myeloproliferative Neoplasms (MPN), sponsored by Hannover Medical School. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Hannover Medical School · Not applicable, Interventional, and Treatment
Among 54 studies in Myeloproliferative Disorders with a site in Germany — 7 open to participants now, 18 under way, 5 of them phase 3. Myeloproliferative Disorders · Germany.
Among the 54 studies in Myeloproliferative Disorders with a site in Germany, this one is the 37th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 53rd registered.
667 studies on the registry are indexed under Myeloproliferative Disorders; 110 are open to participants now.
Browse Myeloproliferative Disorders studies →7 of the 54 studies in Myeloproliferative Disorders with a site in Germany are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Germany, United States, Australia and 8 more countries
Incyte Corporation · Sites in Germany, United States, Australia and 2 more countries
iOMEDICO AG · Sites in Germany
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 26 more countries
Cogent Biosciences, Inc. · Sites in Germany, United States, Australia and 11 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 18 · Phase 3 21 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 80 is above the median of 47 across 462 interventional studies indexed under Myeloproliferative Disorders.
Median enrollment 166 across the 48 interventional studies, 442 across the 5 observational. Of the 34 that completed or were terminated, 21 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 54 have an industry lead sponsor. The 10 most frequent:
Hannover Medical School is the lead sponsor of 202 studies on the registry; 25 are open to participants now.
Hannover Medical School has 1 study filed under Myeloproliferative Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Myeloproliferative Disorders with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01761968ItalfarmacoLong-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | 2026-12 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT07384039Hannover Medical SchoolExercise Training in Patients With Myeloproliferative Neoplasms | 2026-12-31 |
Among the 54 studies in Myeloproliferative Disorders with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators will investigate the response of an individualized exercise training program on quality of life, cardiorespiratory fitness and disease-specific markers in patients with myeloproliferative neoplasms (MPN). To this end, the investigators will randomly assign patients with MPN to a training group and a waiting control group.
The training group will undergo an individually tailored exercise training program for three months, while the control group will maintain their usual lifestyle for three months and then has the opportunity to undergo the three-month intervention program. At the beginning and at the end of the three-month intervention phase, the investigators will evaluate physical performance, daily physical activity, muscular strength, and self-reported outcomes and compare them between the training and the control group, in order to assess potential benefits of the exercise training program.
To date, there have been no randomized intervention studies on the effects of physical training in patients with myeloproliferative neoplasms (MPN). Current leukemia and hematology society recommendations and guidelines support the engagement in regular physical activity to improve cardiovascular health, reduce fatigue, and enhance quality of life. However, no disease-specific exercise guidelines for patients with MPNs exist due to the lack of appropriate clinical trials adressing this issue. The aim of the planned study is to investigate an individually tailored physical exercise program with online monitoring for patients with MPN and to measure its effects on quality of life and physical fitness. The primary endpoint is performance (watts) at the respiratory compensation point (RCP), an established marker of submaximal physical performance.
This is a monocentric, prospective, randomized intervention study with a waiting control group. Randomization is performed in a 1:1 ratio to the study groups and is stratified for gender (male/female). The persons conducting the exercise tests (but not the trainers guiding the training program) are blinded so that there is no targeted motivation during the performance test of the intervention group.
Description of the study procedure: The intervention lasts 3 months. The waiting-control group receives the intervention after the 3-month control phase. Participants receive feedback every second week during intervention via telemonitoring or in person, depending on their distance from the study center.
The intervention includes structured, individually tailored physical training with feedback and adjustments to physical activity intensity and content. Daily activity is monitored using a wearable activity device (Garmin smartwatch). An individual training plan includes moderate endurance and strength exercises 3 times a week, with the goal of being physically active for 150 minutes per week. To avoid overexertion, training is monitored by measuring heart rate and providing individual feedback to patients.
The primary evaluation follows the intention-to-treat (ITT) principle, with missing values at the final examination replaced by the corresponding baseline values. An analysis of covariance (ANCOVA) model is used for performance at the RCP, with the mean after-before difference as the primary target variable. Covariates included in the model are the therapy group (intervention and waiting list control), the baseline values of the performance parameter, and gender (female/male). The intervention is considered successful if the lower limit of the two-sided 95% confidence interval is greater than 0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients randomized to the 3-month guided exercise training program
Behavioral: Exercise Training
Patients randomized to the wait-list control group will maintain their usual lifestyle for the three months intervention period. After this period, they will have the opportunity to participate at the same intervention provided to the exercise training group.
The intervention includes structured and tailored physical training with individual feedback and adjustments to training frequency, intensity, time and content for a total duration of 3 months. Daily activity is monitored using a wearable activity device (Vivoactive 5, Garmin, Olathe, Kansas, USA). An individual training plan includes moderate endurance and strength exercises usually 3 times a week, with the goal of being physically active for at least 150 minutes per week. Participants receive feedback at least every second week via telemonitoring or in person, depending on their distance from the study center. To avoid overexertion, training is monitored by measuring heart rate and providing individual feedback for adjustments if neccesary.
Change in power output (in watt) at the respiratory compensation point (RCP)
During an incremental exercise test on a bicycle ergometer power output and gas exchange will be measured continuously. Afterwards the RCP (also known as second ventilatory threshold) will be assessed based on the inflection point of the slopes of the tidal volume (VE) and the carbon dioxide output (VCO2).
Time frame: From baseline to the end of the intervention period at 3 months
Change of the Myeloproliferative Neoplasm-10 (MPN-10) score by 30% (yes/no)
Evaluation of the MPN-10, a validated, patient-reported outcome questionnaire specifically designed to assess the symptoms and quality of life in patients with myeloproliferative neoplasms. MPN-10 assesses 10 key symptoms commonly experienced by MPN patients. Scoring: 0-4 scale per item, total score ranges from 0 to 40. If the total score is reduced by 30% the binary outcome (yes/no) is fulfilled.
Time frame: From baseline to the end of the intervention period at 3 months
Change in peak oxygen uptake (VO2 in ml/min/kg)
During an incremental bicycle exercise test until voluntary exhaustion gas exchange will be measured continuously breath by breath. Within the last stage, the highest oxygen uptake values from single breaths during 30 consecutive seconds are determined as the peak oxygen uptake.
Time frame: From baseline to the end of the intervention period at 3 months
Change in daily physical activity (MET-hours/week)
To estimate the total and exercise-related physical activity, metabolic equivalents of task (MET) as MET-hours per week will be calculated, using the International Physical Activity Questionnaire (IPAQ-long) as self-reported outcome
Time frame: From baseline to the end of the intervention period at 3 months
Change in EORTC QLQ-C30 scores
The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 is an internationally used, standardized questionnaire from the European Organization for Research and Treatment of Cancer (EORTC) that assesses health-related quality of life (HrQoL) in cancer patients, measuring functioning (physical, role, emotional, cognitive, social) and symptoms (fatigue, pain, nausea/vomiting). It uses scales from 0-100, where higher scores mean better function/HrQoL (for function scales) or worse symptoms (for symptom scales). Further, a summary score can be calculated by averaging 13 scales (after reversing symptom scales) to provide one overall measure of HrQoL, with higher scores meaning better functioning/HrQoL, and scores range from 0-100.
Time frame: From baseline to the end of the intervention period at 3 months
Change in the FACT-Leu Score
The Functional Assessment of Cancer Therapy - Leukemia (FACT-Leu) is a valid measure of leukemia-specific health-related quality of life (HrQoL) for acute and chronic disease. Assessed subscales include Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and a Leukemia Subscale with overall 44 items that has to be responded on a 5 point Likert-type scale. Subscale scores and a total score with a range from 0 to 176 points are possible, with higher scores indicate better HrQoL.
Time frame: From baseline to the end of the intervention period at 3 months
Change in power output (in watt) at the Ventilatory Threshold (VT)
During the incremental exercise test on a bicycle ergometer power output and gas exchange will be measured continuously. Afterwards the VT will be assessed based on the inflection point of the slopes of the carbon dioxide output (VCO2) and the ventilated oxygen (VO2).
Time frame: From baseline to the end of the intervention period at 3 months
Change in steps per day
Number of steps will be recorded by a wearable activity tracker (Vivoactive 5, Garmin, Olathe, Kansas, USA) during 7 consecutive days. Valid days will be averaged to get the outcome steps/day.
Time frame: From baseline to the end of the intervention period at 3 months
Change in lactate dehydrogenase (LDH in U/L)
LDH is released into the bloodstream upon cellular damage or increased turnover. In patients with MPNs, elevated LDH levels are commonly observed and are associated with increased disease burden, tumor cell proliferation, and adverse prognosis. LDH serves as a non-specific but clinically useful biomarker of disease activity and metabolic stress.
Time frame: From baseline to the end of the intervention period at 3 months
Change in platelet count (in Tsd./µl )
Platelet count is a key component of the complete blood count and reflects bone marrow activity and hemostatic function. In MPNs abnormal platelet production is a hallmark feature, often leading to sustained thrombocytosis (elevated platelet count). Elevated platelet counts are associated with increased risk of thrombotic and hemorrhagic complications, which are major clinical concerns in MPN management.
Time frame: From baseline to the end of the intervention period at 3 months
Change in growth differentiation factor 15 (GDF15 in ng/l)
GDF15 is produced by a variety of tissues in response to cellular stress, inflammation, oxidative damage, and mitochondrial dysfunction. Elevated serum GDF15 levels are associated with aging, chronic inflammation, and several hematologic and malignant conditions. In MPNs, GDF15 is often upregulated due to increased bone marrow stress, dysregulated hematopoiesis, and systemic inflammation. Higher GDF15 levels correlate with disease burden, symptom burden, and adverse outcomes, making it a potential biomarker of disease activity and systemic stress.
Time frame: From baseline to the end of the intervention period at 3 months
Change in soluble interleukin-2 receptor (sIL-2R in KU/l)
SIL-2R serves as a biomarker of immune system activation and lymphocyte proliferation. Elevated serum levels of sIL-2R are associated with chronic inflammation, autoimmune disorders, and hematologic malignancies. In MPNs, persistent immune dysregulation and chronic inflammation contribute to disease pathogenesis and symptom burden, and sIL-2R levels often correlate with disease activity, inflammatory burden, and clinical progression.
Time frame: From baseline to the end of the intervention period at 3 months
Plan to share: Yes — De-identified individual participant data that underlie the results of the publication will be available upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: beginning 6 months after publication and ending 5 years after publication.
Access criteria: Data will be shared with researchers who provide a methodologically sound proposal to achieve aims in the approved proposal. Proposals should be directed to sportmedizin@mh-hannover.de to gain access, data requestors will need to sign a data-use agreement.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 26 interventional studies with no phase under Myeloproliferative Disorders, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 128. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myeloproliferative Disorders →